Observational studyUnited European gastroenterology journal2026
Molecular Traces of Gastric Cancer in Saliva: From Tissue Signatures to Salivary SLC5A5 as a Potential Biomarker.
Observational study in United European gastroenterology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundEarly detection of gastric cancer (GC) and reliable risk stratification for metachronous gastric lesions (MGLs) remain societal and clinical challenges, particularly in intermediate risk populations. Non-invasive approaches such as saliva-based biomarkers could complement current strategies. The aim of this study was to identify and validate a tissue-based gene expression signature for early gastric lesions, explore its potential for MGL prediction, and assess its detectability in saliva.
methodsThree studies were conducted: (1) a retrospective case control study to identify (RNA sequencing with machine learning) and validate (reverse transcription [RT] quantitative polymerase chain reaction [qPCR]) a gene expression signature for early gastric cancer using formalin-fixed paraffin-embedded (FFPE) samples, (2) a retrospective longitudinal study evaluating the ability of the signature to stratify MGL risk, and (3) a prospective study testing the signature in saliva using droplet digital (dd)PCR in patients with gastric lesions and endoscopy-confirmed controls.
resultsA six-gene tissue-based expression signature (ADAMTSL1, CCNA2, HSP90AB1, HSPD1, PSAPL1, and SLC5A5) robustly discriminated early gastric lesions from non-tumor mucosa (area under the curve (AUC) = 0.96 and 95% confidence interval [CI]: 0.94-0.99). Models tailored for MGL prediction, incorporating clinical variables, achieved moderate performance (AUC = 0.74 and 95% CI: 0.59-0.88). In saliva, only the SLC5A5 gene showed consistent dysregulation. When combined with age and sex, the model reached an AUC of 0.78 (95% CI: 0.69-0.88) for the non-invasive detection of early GC, with a positive predictive value of 0.69 and negative predictive value of 0.81.
conclusionThis study presents a validated tissue-based gene signature for early GC detection and exploratory MGL risk stratification. Salivary SLC5A5 shows potential as a non-invasive biomarker, though its utility requires further validation in dedicated saliva-based studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.